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similar, all transthoracic esophagecto-
mies are not equal.
Drs Chang and McAnena also refer-
ence a report by Kinugasa et al and
raise the concern that pulmonary com-
plications may have adversely im-
pacted long-term survival in the
transhiatal group in our study.4 It is
important to recognize that all patients
in the study by Kinugasa et al had
squamous cell cancer, and many had
3-field lymph node dissections. Pul-
monary dysfunction is more likely in
patients with squamous cancer and
a significant smoking history, and re-
current laryngeal nerve palsy is more
common after a 3-field dissection
than after our 2-field lymphadenec-
tomy. Nonetheless, pulmonary com-
plications are known to be more
common after transthoracic esopha-
gectomy, so this is unlikely to be the
cause of the worse survival in the tran-
shiatal group. We recognize that pa-
tients who had a transhiatal resection
were older and had more comorbid-
ities, and consequently, we analyzed
disease-specific survival for both
groups and showed that the difference
in favor of the en bloc resection was
even more striking. Because all pa-
tients had advanced disease based on
preoperative clinical staging and
many had residual disease after ther-
apy, we do not believe that a Cox anal-
ysis of relatively minor factors such as
lymphovascular invasion and tumor
differentiation would alter or add to
the very clear findings in favor of an
en bloc resection in our data.
We agree that stage migration likely
explains some of the difference in
survival that we found in the group
of patients with complete pathologic
response in favor of the en bloc resec-
tion group. However, the concern of
stage migration is precisely why our
finding of significantly improved sur-
vival in patients with residual disease
after en bloc resection is so important,
because stage migration is not possible
in these patients: they all had residual
disease, and survival in these patients
is known to be poor. In our opinion,
there is no valid explanation for the
difference in survival we report other
than the type of resection and, in
particular, the reduced incidence of
local-regional recurrence after the en
bloc technique. It is likely that even
in patients thought to have complete
pathologic response, the en bloc resec-
tion provides a survival advantage by
the removal of micrometastatic disease
that would otherwise be left behind
with a transhiatal resection. The ‘‘un-
derestimation of residual disease’’
only applies to the group with sup-
posed complete pathologic response,
and, importantly, this is the only group
without a significant improvement in
survival with the en bloc procedure.
When residual disease was present,
and therefore not underestimated, the
patients who had en bloc resection
had a significant survival advantage
over those who had transhiatal resec-
tion. If Drs Chang and McAnena are
implying that the disease is underesti-
mated even in this group of patients
who had a transhiatal resection, that
may well be true, but that is also the
point: residual disease needs to be re-
moved to provide patients with a sur-
vival advantage, and the en bloc
esophagectomy is the best procedure
to accomplish this objective.
We recognize that some centers
have reported a high prevalence of
upper mediastinal and cervical nodal
disease even with distal esophageal ad-
enocarcinomas, but this has not been
our experience. Our preference is to
carefully watch these areas with serial
computed tomography and positron
emission tomography scans and to
reoperate when necessary for nodal re-
currence. It has not been our experi-
ence that the failure rate for localized
nodal recurrence in these areas is high
enough to justify the added morbidity
of a 3-field dissection in everyone.
On a last note, we ask that readers
keep an open mind about the possibil-
ity, or perhaps probability, that the
type of resection does impact survival
for patients with esophageal cancer
and consider doing a thorough node
dissection in the chest and abdomen
for all patients, including those who
have had neoadjuvant therapy. After
all, local control is what we as sur-
geons provide to patients with esopha-
geal cancer, and the evidence is
becoming irrefutable that this is best
accomplished with a transthoracic en
bloc esophagectomy.
Dr. Steven R. DeMeester
Department of Surgery
University of Southern California
Los Angeles, Calif
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Letters to the Editor




We read with considerable interest
the study by Marra and colleagues1
in the April 2008 issue, ‘‘Remediasti-
noscopy in Restaging of Lung Cancer
After Induction Therapy.’’ We do,
however, have some issues with the
statistical interpretation of their
results.
First, there is the reporting of a P
value of 0.0000 in their Table 2.1 A
P value is the probability of observing
the value or more extreme values
given that the null hypothesis is true
(ie, no true difference). Marra and col-
leagues1 give this as 0, which is not9
Reply to the Editor:
We thank Drs Lim and Dusmet
for their comments. We would like to
answer some issues they addressed in
the statistical analysis of our article.
As concerns the need to report
specificity, competing methods for
mediastinal restaging are of noninva-
sive (positron emission tomography,
integrated positron emission tomogra-
phy and computed tomography), or
invasive (endoesophageal ultrasonog-
raphy with fine-needle aspiration bi-
opsy, endobronchial ultrasonography
with transbronchial needle aspiration,
remediastinoscopy) nature. Noninva-
sive methods do not provide histologic
proof of their positive findings, so spec-
ificity varies to a high of 90% (and thus
is lower than 100%). Invasive methods
are able to provide a histologic or cyto-
logic biopsy specimen of lymph nodes.
In the first case, specificity is as high
as 100%; in the second, however,
cytologic examination may yield false-
positive findings. In a review of the
literature on cytologic study in pulmo-
nary medicine, Policarpio-Nicolas and
Wick1 reported overall sensitivity and
specificity values ranging from 60%
to 96%, even in the most conscientious
laboratories and considering the in-
creased confidence of pathologists in
cytomorphologic diagnosis.
The reported value of sensitivity of
61% in our series is consistent with
the previous literature on remediasti-
noscopy (70%–83%), if slightly
lower, with the exception of the study
of De Leyn and colleagues,2 who re-
ported a disappointing 29% sensitivity
in a small series of patients. That report
was heavily biased by the inadequate
reexploration of the subcarinal station
in two thirds of cases (in which persis-
tent nodal disease was found in 50%
of cases at thoracotomy) and thus can-
not be cited as a standard reference for
the diagnostic value of remediastino-
scopy. In most cases, sensitivity values
of remediastinoscopy are comparable
to or higher than those of the other
methods for mediastinal restaging.
Letters to the Editorpossible, when what they mean is that
the probability (P value) is less than
.0001. They do not state in the table
to what test or null hypothesis the P
value refers, so it is not possible for
the reader to interpret the statistical
significance.
Second, Marra and colleagues1 re-
port that remediastinoscopy is associ-
ated with 100% specificity. That in
itself is to be expected, simply
because for the vast majority of tests
(endobronchial ultrasonography in-
cluded) performed with diagnostic bi-
opsy, when tumor is seen in a biopsy
specimen, it is invariably confirmed
on the reference test (there would be
serious problems if tumor diagnosed
on the index test proved to be normal
on the reference test). Therefore spec-
ificity (ability to rule in disease) is not
the major focus for surgeons when
evaluating remediastinoscopy for re-
staging the mediastinum. The same
specificity will be obtained with any
other tests combined with tissue bi-
opsy, such as endobronchial ultraso-
nography (as referenced by Marra
and colleagues1).
Third, what is critical is sensitivity
(the ability to rule out disease), so that
patients with residual N2 disease
are not brought to operation mistak-
enly, and the reported sensitivity for
remediastinoscopy was 61%. It is im-
portant for readers to bear in mind
that sensitivity truly starts at 50% (a
test with no sensitivity, or equipoise),
not 0%. Marra and colleagues1 do not
report a confidence interval for this es-
timate; when one is calculated, it ranges
from 42% to 77%. That is, it crosses
50%. This low value of sensitivity is
entirely in keeping with the previous
literature on remediastinoscopy. De
Leyn and associates2 attributed this to
the technical difficulty in obtaining ad-
equate biopsy specimens from the areas
of previous lymph node involvement.
Fourth, Marra and colleagues1 have
used their own arbitrary definition of
‘‘diagnostic accuracy,’’ which includes
(see footnote in their Table 3) in the de-
nominator ‘‘no biopsy.’’ This does notThe Journcomply with current Standards for
Reporting of Diagnostic Accuracy
(STARD).3 The importance of STARD
was previously highlighted by Eugene
Blackstone4 in this Journal in 2004.
We believe that compliance with
STARD is crucial for readers (which is
why it is part of this Journal’s policy),
andwe are surprised that a non–STARD
compliant article was highlighted for
continuing medical education credit.
On the basis of these findings, we
believe that the conclusion that ‘‘re-
mediastinoscopy provides a histologic
proof of mediastinal downstaging with
high diagnostic accuracy’’ cannot be
sustained by the results presented by
Marra and colleagues.1 The results do
indicate that residual disease can ruled
in with repeated mediastinoscopy, but
the procedure is unable to rule out
residual mediastinal disease with any
degree of certainty (sensitivity of
61%, 95% confidence interval 42%–
77%). Futile thoracotomy thus would
not be avoided for a large proportion
of patients were this technique used
to restage the mediastinum after induc-
tion chemotherapy.
Eric Lim, MB, ChB, MD, MSc,
(Biostatistics), FRCS (C-Th)
Michael Dusmet, MD, FMH
The Royal Brompton Hospital
London, UK
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